Work

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-168930

Authors: Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Institutions: Mayo Clinic, Moffitt Cancer Center, University of Maryland, Baltimore, University of Kansas Medical Center, Medical College of Wisconsin, Weill Cornell Medicine, Fred Hutch Cancer Center, Levine Cancer Institute, University of Chicago, Cedars-Sinai Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310127406

FWCI: 5.166

Cites:

Cited by: 45

Related to: 10